Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present at two virtual investor conferences. The 33rd Annual Virtual Roth Conference is scheduled for March 16, 2021 at 1:30 PM EST, followed by the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 at 1:10 PM EST. Both events will include a fireside chat and Q&A session. Investors can access audio webcasts and replays on the Corbus website. Corbus develops innovative medicines targeting the endocannabinoid system, with its lead candidate, lenabasum, in trials for inflammatory diseases.

Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences.

 The following are the details for the conferences:

33^rd Annual Virtual Roth Conference

• Event: Fireside Chat Discussion and Q&A
• Date and Time: Tuesday, March 16, 2021 at 1:30 PM EST

Oppenheimer 31^st Annual Healthcare Conference

• Event: Fireside Chat Discussion and Q&A
• Date and Time: Wednesday, March 17, 2021 at 1:10 PM EST

An audio webcast of the presentations will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. Replays will be available approximately one hour after each event and will be archived for 90 days following the event.

About Corbus 

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.

For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Contacts:

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com

FAQ

When will Corbus Pharmaceuticals present at the Roth Conference?

Corbus Pharmaceuticals will present at the 33rd Annual Virtual Roth Conference on March 16, 2021, at 1:30 PM EST.

What is the date of the Oppenheimer Healthcare Conference presentation by CRBP?

The Oppenheimer 31st Annual Healthcare Conference presentation by Corbus Pharmaceuticals is on March 17, 2021, at 1:10 PM EST.

How can I listen to the Corbus Pharmaceuticals conference presentations?

Audio webcasts of the Corbus Pharmaceuticals presentations will be available on their website, with replays for 90 days after each event.

What is lenabasum and its potential use?

Lenabasum is a novel cannabinoid receptor type 2 (CB2) agonist being developed by Corbus, aimed at treating chronic inflammatory and fibrotic diseases.

What does Corbus Pharmaceuticals focus on?

Corbus Pharmaceuticals focuses on developing and commercializing innovative medicines targeting the endocannabinoid system.